S
S

Sanofi

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Financial Times - Aug 18

Aug 18 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Ofgem director quits in protest at changes to price cap calculation Link - Genesis CEO exits after crypto broker took hit from Three Arrows collapse Link - Sanofi drops experimental breast cancer drug after second trial fails Link - Jim Ratcliffe declares interest in buying Manchester United Link Overview - A board member of Ofgem
S

UK first to approve Omicron COVID shot with Moderna nod

* UK's JCVI backs using bivalent shot in autumn booster campaign * Moderna sees Australia, Canada, EU approvals soon By Natalie Grover LONDON, Aug 15 (Reuters) - Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus.
A
G
P
S

European shares eke out gains at open as healthcare stocks rebound

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) Aug 12 (Reuters) - European shares eked out gains on Friday at the open after Sanofi and GSK led a rebound in healthcare stocks, with the main STOXX 600 index set for weekly gains. Sanofi SASY.PA rose 1.6% and GSK GSK.L added 3.0% after a heavy selloff in the previous session on growing worries about U.S.
S
E
F
U
G

UK Stocks-Factors to watch on Aug 12

Aug 12 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening flat with futures .FFIc1 up 0.1% on Friday. * FLUTTER: Flutter FLTRF.I posted a 20% fall in first-half earnings but expects to finish the year ahead of 2021 excluding an expected final year of losses in its fast growing U.S. business. * 888 HOLDINGS: 888 Holdings Plc 888.L reported a fall in its interim profit, hurt by tightened UK online gambling safety measures and the cost-of-living crisis.
A
S
F
N
U

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

By Natalie Grover LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday. "We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said, responding to Reuters querying a near-20% decline in Haleon's share price this week.
G
P
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.